Antibody signatures are found to predict treatment success for two leading checkpoint inhibitors.

Dr. David J. Byun says the role and optimal duration of hormone therapy continue to remain controversial.

Dr. Ruth Oratz says that while the study results are exciting, more research needs to be done.

Dr. Maya Dimitrova says tumor-infiltrating lymphocyte therapy could expand available melanoma treatments.

The combination of olaparib and bevacizumab represents a new standard of care, Dr. Eva Chalas says.

Dr. Oren Cahlon has been appointed senior vice president and deputy chief clinical officer.

Dr. Elisabeth J. Cohen is enhancing the department’s longstanding commitment to research.

Together, psilocybin and psychotherapy reduced alcohol consumption by 83 percent among heavy drinkers.

Dr. Elaine Shum is leading this trial, which aims to fill an unmet need for targeted therapies.

Joining the Experimental Therapeutics Clinical Trials Network advances cancer clinical trial capabilities.